Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice

Virology

Volumn 462-463, Issue 1, 2014, Pages 115-125

  Stoddart, Cheryl A ^a   Galkina, Sofiya A ^a   Joshi, Pheroze ^a   Kosikova, Galina ^a   Long, Brian R ^a   Maidji, Ekaterina ^a   Moreno, Mary E ^a   Rivera, Jose M ^a   Sanford, Ukina R ^a   Sloan, Barbara ^a   Cieplak, Witold ^b   Wrin, Terri ^c   Chan Hui, Po Ying ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Theraclone Sciences Inc   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

Author keywords

HIV infection; HIV pathogenesis; Humanized mouse; Neutralizing antibody; Passive immunization

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PG16; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLADISTICS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION;

HIV INFECTION; HIV PATHOGENESIS; HUMANIZED MOUSE; NEUTRALIZING ANTIBODY; PASSIVE IMMUNIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; MALE; MICE; MICE, SCID; TREATMENT OUTCOME;

EID: 84902991214     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.05.036     Document Type: Article

References (55)

1. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59:284-291.
2. Amado R.G, Jamieson B.D., Cortado R., Cole S.W., Zack J.A. Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy. J. Virol. 1999, 73:6361-6369.
3. Bleck G.T. Consistent production of genetically stable mammalian cell lines. BioPharm Int. 2012, 25:56-59.
4. Bonsignori M., Hwang K.K., Chen X., Tsao C.Y., Morris L., Gray E., Marshall D.J., Crump J.A., Kapiga S.H., Sam N.E., Sinangil F., Pancera M., Yongping Y., Zhang B., Zhu J., Kwong P.D., O'Dell S., Mascola J.R., Wu L., Nabel G.J., Phogat S., Seaman M.S., Whitesides J.F., Moody M.A., Kelsoe G., Yang X., Sodroski J., Shaw G.M., Montefiori D.C., Kepler T.B., Tomaras G.D., Alam S.M., Liao H.X., Haynes B.F. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 2011, 85:9998-10009.
5. Burton D.R., Hessell A.J., Keele B.F., Klasse P.J., Ketas T.A., Moldt B., Dunlop D.C., Poignard P., Doyle L.A., Cavacini L., Veazey R.S., Moore J.P. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Nat. Acad. Sci. U.S.A. 2011, 108:11181-11186.
6. Cann A.J., Zack J.A., Go A.S., Arrigo S.J., Koyanagi Y., Green P.L., Pang S., Chen I.S. Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J. Virol. 1990, 64:4735-4742.
7. Covassin L., Jangalwe S., Jouvet N., Laning J., Burzenski L., Shultz L.D., Brehm M.A. Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rγ(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells. Clin. Exp. Immunol. 2013, 174:372-388.
8. Davenport T.M., Friend D., Ellingson K., Xu H., Caldwell Z., Sellhorn G., Kraft Z., Strong R.K., Stamatatos L. Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16. J. Virol. 2011, 85:7095-7107.
9. Diskin R., Klein F., Horwitz J.A., Halper-Stromberg A., Sather D.N., Marcovecchio P.M., Lee T., West A.P., Gao H., Seaman M.S., Stamatatos L., Nussenzweig M.C., Bjorkman P.J. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J. Exp. Med. 2013, 210:1235-1249.
10. Diskin R., Scheid J.F., Marcovecchio P.M., West A.P., Klein F., Gao H., Gnanapragasam P.N., Abadir A., Seaman M.S., Nussenzweig M.C., Bjorkman P.J. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011, 334:1289-1293.
11. Dittmer D., Stoddart C., Renne R., Linquist-Stepps V., Moreno M.E., Bare C., McCune J.M., Ganem D. Experimental transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to SCID-hu Thy/Liv mice. J. Exp. Med. 1999, 190:1857-1868.
12. Doores K.J., Burton D.R. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 2010, 84:10510-10521.
13. Falkowska E., Ramos A., Feng Y., Zhou T., Moquin S., Walker L.M., Wu X., Seaman M.S., Wrin T., Kwong P.D., Wyatt R.T., Mascola J.R., Poignard P., Burton D.R. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 2012, 86:4394-4403.
14. Fenyo E.M., Heath A., Dispinseri S., Holmes H., Lusso P., Zolla-Pazner S., Donners H., Heyndrickx L., Alcami J., Bongertz V., Jassoy C., Malnati M., Montefiori D., Moog C., Morris L., Osmanov S., Polonis V., Sattentau Q., Schuitemaker H., Sutthent R., Wrin T., Scarlatti G. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 2009, 4:e4505.
15. Gauduin M.C., Parren P.W., Weir R., Barbas C.F., Burton D.R., Koup R.A. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 1997, 3:1389-1393.
16. Greenblatt M.B., Vrbanac V., Tivey T., Tsang K., Tager A.M., Aliprantis A.O. Graft versus host disease in the bone marrow, liver and thymus humanized mouse model. PLoS One 2012, 7:e44664.
17. Haltiner M., Kempe T., Tjian R. A novel strategy for constructing clustered point mutations. Nucleic Acids Res. 1985, 13:1015-1025.
18. Hessell A.J., Poignard P., Hunter M., Hangartner L., Tehrani D.M., Bleeker W.K., Parren P.W., Marx P.A., Burton D.R. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009, 15:951-954.
19. Hessell A.J., Rakasz E.G., Poignard P., Hangartner L., Landucci G., Forthal D.N., Koff W.C., Watkins D.I., Burton D.R. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5:e1000433.
20. Hessell A.J., Rakasz E.G., Tehrani D.M., Huber M., Weisgrau K.L., Landucci G., Forthal D.N., Koff W.C., Poignard P., Watkins D.I., Burton D.R. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 2010, 84:1302-1313.
21. Heyndrickx L., Heath A., Sheik-Khalil E., Alcami J., Bongertz V., Jansson M., Malnati M., Montefiori D., Moog C., Morris L., Osmanov S., Polonis V., Ramaswamy M., Sattentau Q., Tolazzi M., Schuitemaker H., Willems B., Wrin T., Fenyo E.M., Scarlatti G. International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One 2012, 7:e36438.
22. Horwitz J.A., Halper-Stromberg A., Mouquet H., Gitlin A.D., Tretiakova A., Eisenreich T.R., Malbec M., Gravemann S., Billerbeck E., Dorner M., Büning H., Schwartz O., Knops E., Kaiser R., Seaman M.S., Wilson J.M., Rice C.M., Ploss A., Bjorkman P.J., Klein F., Nussenzweig M.C. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:16538-16543.
23. Klein F., Halper-Stromberg A., Horwitz J.A., Gruell H., Scheid J.F., Bournazos S., Mouquet H., Spatz L.A., Diskin R., Abadir A., Zang T., Dorner M., Billerbeck E., Labitt R.N., Gaebler C., Marcovecchio P.M., Incesu R.B., Eisenreich T.R., Bieniasz P.D., Seaman M.S., Bjorkman P.J., Ravetch J.V., Ploss A., Nussenzweig M.C. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012, 492:118-122.
24. Kovalev G., Duus K., Wang L., Lee R., Bonyhadi M., Ho D., McCune J.M., Kaneshima H., Su L. Induction of MHC class I expression on immature thymocytes in HIV-1-infected SCID-hu Thy/Liv mice: evidence of indirect mechanisms. J. Immunol. 1999, 162:7555-7562.
25. Koyanagi Y., Miles S., Mitsuyasu R.T., Merrill J.E., Vinters H.V., Chen I.S. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 1987, 236:819-822.
26. Lan P., Tonomura N., Shimizu A., Wang S., Yang Y.G. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 2006, 108:487-492.
27. Lobo E.D., Hansen R.J., Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 2004, 93:2645-2668.
28. Long B.R., Stoddart C.A. Alpha interferon and HIV infection cause activation of human T cells in NSG-BLT mice. J. Virol. 2012, 86:3327-3336.
29. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., Louder M.K., Brown C.R., Sapan C.V., Frankel S.S., Lu Y., Robb M.L., Katinger H., Birx D.L. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 1999, 73:4009-4018.
30. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000, 6:207-210.
31. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., O'Dell S., Patel N., Shahzad-ul-Hussan S., Yang Y., Zhang B., Zhou T., Zhu J., Boyington J.C., Chuang G.Y., Diwanji D., Georgiev I., Kwon Y.D., Lee D., Louder M.K., Moquin S., Schmidt S.D., Yang Z.Y., Bonsignori M., Crump J.A., Kapiga S.H., Sam N.E., Haynes B.F., Burton D.R., Koff W.C., Walker L.M., Phogat S., Wyatt R., Orwenyo J., Wang L.X., Arthos J., Bewley C.A., Mascola J.R., Nabel G.J., Schief W.R., Ward A.B., Wilson I.A., Kwong P.D. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
32. Melkus M.W., Estes J.D., Padgett-Thomas A., Gatlin J., Denton P.W., Othieno F.A., Wege A.K., Haase A.T., Garcia J.V. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 2006, 12:1316-1322.
33. Moldt B., Rakasz E.G., Schultz N., Chan-Hui P.Y., Swiderek K., Weisgrau K.L., Piaskowski S.M., Bergman Z., Watkins D.I., Poignard P., Burton D.R. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Nat. Acad. Sci. U.S.A. 2012, 109:18921-18925.
34. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., Palese P., Katinger H. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 1994, 68:4031-4034.
35. Namikawa R., Weilbaecher K.N., Kaneshima H., Yee E.J., McCune J.M. Long-term human hematopoiesis in the SCID-hu mouse. J. Exp. Med. 1990, 172:1055-1063.
36. Pancera M., McLellan J.S., Wu X., Zhu J., Changela A., Schmidt S.D., Yang Y., Zhou T., Phogat S., Mascola J.R., Kwong P.D. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 2010, 84:8098-8110.
37. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 2001, 75:8340-8347.
38. Pejchal R., Walker L.M., Stanfield R.L., Phogat S.K., Koff W.C., Poignard P., Burton D.R., Wilson I.A. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc. Nat. Acad. Sci. U.S.A. 2010, 107:11483-11488.
39. Poignard P., Sabbe R., Picchio G.R., Wang M., Gulizia R.J., Katinger H., Parren P.W., Mosier D.E., Burton D.R. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999, 10:431-438.
40. Rabin L., Hincenbergs M., Moreno M.B., Warren S., Linquist V., Datema R., Charpiot B., Seifert J., Kaneshima H., McCune J.M. Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. Antimicrob. Agents Chemother. 1996, 40:755-762.
41. Richman D.D., Wrin T., Little S.J., Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Nat. Acad. Sci. U.S.A. 2003, 100:4144-4149.
42. Roben P., Moore J.P., Thali M., Sodroski J., Barbas C.F., Burton D.R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 1994, 68:4821-4828.
43. Sagar M., Akiyama H., Etemad B., Ramirez N., Freitas I., Gummuluru S. Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection. J. Infect. Dis. 2012, 205:1248-1257.
44. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T.Y., Pietzsch J., Fenyo D., Abadir A., Velinzon K., Hurley A., Myung S., Boulad F., Poignard P., Burton D.R., Pereyra F., Ho D.D., Walker B.D., Seaman M.S., Bjorkman P.J., Chait B.T., Nussenzweig M.C. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637.
45. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 2001, 17:1757-1765.
46. Stoddart C.A., Bales C.A., Bare J.C., Chkhenkeli G., Galkina S.A., Kinkade A.N., Moreno M.E., Rivera J.M., Ronquillo R.E., Sloan B., Black P.L. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PLoS One 2007, 2:e655.
47. Stoddart C.A., Moreno M.E., Linquist-Stepps V.D., Bare C., Bogan M.R., Gobbi A., Buckheit R.W., Bedard J., Rando R.F., McCune J.M. Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice. Antimicrob. Agents Chemother. 2000, 44:783-786.
48. Stoddart C.A., Nault G., Galkina S.A., Bousquet-Gagnon N., Bridon D., Quraishi O. Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy/Liv mice. Antimicrob. Agents Chemother. 2012, 56:2162-2165.
49. Su L., Kaneshima H., Bonyhadi M., Salimi S., Kraft D., Rabin L., McCune J.M. HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. Immunity 1995, 2:25-36.
50. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 1996, 70:1100-1108.
51. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.P., Wang S.K., Ramos A., Chan-Hui P.Y., Moyle M., Mitcham J.L., Hammond P.W., Olsen O.A., Phung P., Fling S., Wong C.H., Phogat S., Wrin T., Simek M.D., Koff W.C., Wilson I.A., Burton D.R., Poignard P. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
52. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Protocol G.P.I., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
53. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., Longo N.S., McKee K., O'Dell S., Louder M.K., Wycuff D.L., Feng Y., Nason M., Doria-Rose N., Connors M., Kwong P.D., Roederer M., Wyatt R.T., Nabel G.J., Mascola J.R. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
54. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., Chen X., Longo N.S., Louder M., McKee K., O'Dell S., Perfetto S., Schmidt S.D., Shi W., Wu L., Yang Y., Yang Z.Y., Yang Z., Zhang Z., Bonsignori M., Crump J.A., Kapiga S.H., Sam N.E., Haynes B.F., Simek M., Burton D.R., Koff W.C., Doria-Rose N.A., Connors M., Mullikin J.C., Nabel G.J., Roederer M., Shapiro L., Kwong P.D., Mascola J.R. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602.
55. Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., Kwon Y.D., Scheid J.F., Shi W., Xu L., Yang Y., Zhu J., Nussenzweig M.C., Sodroski J., Shapiro L., Nabel G.J., Mascola J.R., Kwong P.D. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817.